Arcus Biosciences, Inc.
RCUS
$28.74
$0.020.07%
NYSE
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 141.18% | -48.48% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 141.18% | -48.48% | |||
| Cost of Revenue | -7.38% | 0.83% | |||
| Gross Profit | 31.43% | -19.32% | |||
| SG&A Expenses | -17.24% | 11.54% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.27% | 2.72% | |||
| Operating Income | 28.36% | -17.54% | |||
| Income Before Tax | 28.91% | -20.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 28.91% | -20.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 28.91% | -20.75% | |||
| EBIT | 28.36% | -17.54% | |||
| EBITDA | 29.55% | -18.92% | |||
| EPS Basic | 29.30% | -14.11% | |||
| Normalized Basic EPS | 29.31% | -14.11% | |||
| EPS Diluted | 29.30% | -14.11% | |||
| Normalized Diluted EPS | 29.31% | -14.11% | |||
| Average Basic Shares Outstanding | 0.56% | 5.82% | |||
| Average Diluted Shares Outstanding | 0.56% | 5.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||